VIBRANTZ-TECHNOLOGIES
19.12.2023 08:46:34 CET | Business Wire | Press release
Eramet and Vibrantz Technologies today announced a 10-year agreement whereby Eramet will supply Vibrantz with manganese ore, an essential raw material used in Vibrantz’s portfolio of manganese technologies for lithium-ion battery and other applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218880208/en/
Another significant step in both companies’ commitments to corporate social responsibility and supporting the transition to a lower emission future, the agreement builds on the 20-year Eramet-Vibrantz partnership to create a reliable pathway for Vibrantz’s manganese sulfate manufacture used in the production of electric vehicle (EV) batteries. Eramet’s manganese ore will be sourced from its Gabon mine which will undertake the Initiative for Responsible Mining Assurance’s (IRMA) audit process to align its operations with international best practices.
“This agreement confirms Eramet's ability to satisfy and win the loyalty of its customers and partners by supplying quality ore produced under responsible conditions,” said Christel Bories, Eramet Chairman and CEO. “Eramet is particularly well positioned to become a key responsible player in the battery value chain through our long-life, high-grade deposits in strategic metals, such as manganese in Gabon, lithium in Argentina at Centenario, and nickel and cobalt in Indonesia at Weda Bay.” Bories added that Eramet seeks to have all of its sites IRMA audited by 2026.
This news comes on the heels of Vibrantz’s announcement that it is constructing a pilot facility to process battery-grade high-purity manganese sulfate (HPMSM) at its Tampico, Mexico, site.
“As Vibrantz advances our commitment to becoming a sustainable and world-class specialty chemicals and materials solutions provider, we value our enduring partnership with Eramet,” said D. Michael Wilson, Vibrantz President and CEO. “This agreement allows Vibrantz to leverage both companies’ 50 years of combined expertise in manganese chemicals as we work to make environmentally friendly vehicles a growing reality for millions of consumers.” Wilson also said the company continues to receive positive market reception of its recent HPMSM capacity investments from battery producers and automotive original equipment manufacturers.
Explore Eramet’s activities here and learn more about Vibrantz’s trusted manganese technologies utilized in battery, agriculture, construction, electronics and water treatment end-use markets.
About Eramet
Eramet transforms the Earth’s mineral resources to provide sustainable and responsible solutions to the growth of the industry and to the challenges of the energy transition. Its employees are committed to this through their civic and contributory approach in all the countries where the mining and metallurgical group is present. Eramet recovers and develops metals essential to the construction of a more sustainable world. Fully committed to the era of metals, Eramet’s ambition is to become a reference for the responsible transformation of the Earth’s mineral resources for living well together.
Visit www.eramet.com.
About Vibrantz Technologies
Vibrantz is a leading global provider of specialty chemicals and materials whose purpose is to bring color, performance and vibrancy to life. Serving over 11,000 customers, our products and technologies serve a wide array of applications and make their way into myriad consumer products. With key competencies in particle engineering, glass and ceramic science and color technology, Vibrantz has leading positions in specialty mineral and chemical additives for batteries, electronic components and construction; pigments for paints and coatings, thermoset plastics and thermoplastics; and high-performance glass coatings and porcelain enamel solutions. Headquartered in Houston, Texas, the company employs approximately 5,000 people and operates 65 manufacturing sites across six continents.
Visit vibrantz.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231218880208/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom